Treatment of arterial calcification in patients with chronic limb threatening ischemia with etidronate: protocol of an investigator-initiated multicenter, double blind, placebo-controlled, randomized clinical trial.

Autor: Hoogervorst R; Haga Hospital, HagaZiekenhuis, The Hague, The Netherlands. r.hoogervorst@hagaziekenhuis.nl., van Overhagen H; Haga Hospital, HagaZiekenhuis, The Hague, The Netherlands., de Jong PA; Haga Hospital, HagaZiekenhuis, The Hague, The Netherlands.; UMC Utrecht, The Hague, The Netherlands., Spiering W; Haga Hospital, HagaZiekenhuis, The Hague, The Netherlands.; UMC Utrecht, The Hague, The Netherlands., de Borst GJ; Haga Hospital, HagaZiekenhuis, The Hague, The Netherlands.; UMC Utrecht, The Hague, The Netherlands., Veger HTC; Haga Hospital, HagaZiekenhuis, The Hague, The Netherlands., Mairuhu ATA; Haga Hospital, HagaZiekenhuis, The Hague, The Netherlands., Mali WPTM; Haga Hospital, HagaZiekenhuis, The Hague, The Netherlands.; UMC Utrecht, The Hague, The Netherlands.
Jazyk: angličtina
Zdroj: CVIR endovascular [CVIR Endovasc] 2022 Jun 06; Vol. 5 (1), pp. 26. Date of Electronic Publication: 2022 Jun 06.
DOI: 10.1186/s42155-022-00298-y
Abstrakt: Background: Pathologic studies have shown that in patients with critical limb threatening ischaemia (CLTI) medial arterial calcifications are frequently found and may be responsible for aggravating the disease. These extensive calcifitcations are found not only in arteries of the leg but also in the coronary arteries and the aorta. The progression of these calcifications is fast and they stiffen the vessel wall and may thus increase the cardiovascular risk. Reduction of progression of calcification may not only reduce the burden of CLTI but may also reduce the high residual cardiovascular risk. Medial calcifications have been halted by etidronate in other trials. Its potential to reduce the burden from peripheral vascular disease in CLTI and residual cardiovascular risk remains to be established.
Methods: This is an investigator-initiated multicenter, double blind, placebo-controlled, randomized trial comparing the effects of etidronate versus placebo in patients with CLTI. Subjects will be randomized to either treatment with etidronate for 12 months (cyclical 20 mg/kg for 2 weeks on and 10 weeks off) orally or placebo for 12 months (in a similar routine). The primary endpoint is the change in arterial calcification as quantified by CT-scan. Secondary endpoints are the number of amputations above and below the ankle, mortality, number of vascular interventions and quality of life.
Discussion: Up to now, the inert end stage of vascular disease in patients with CLTI, has been considered calcification of vessel walls. We believe there is reason to reverse causation and hypothesize that calcification causes vascular disease. This reversal can be proven in a clinical trial if halting the calcification process improves the outcome of the patient. Therefore we use etidronate, a bisphosphate that has proven to stop the calcification in several rare monogenetic calcifying diseases. We aim to perform this mechanistic proof-of-concept study hopefully leading to a clinical outcome study later on.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: